Tricida, Inc. (NASDAQ:TCDA) Major Shareholder Sells $125,240.44 in Stock

Tricida, Inc. (NASDAQ:TCDA – Get Rating) major shareholder Brian M. Isern sold 11,804 shares of Tricida stock in a transaction that occurred on Thursday, April 28th. The shares were sold at an average price of $10.61, for a total transaction of $125,240.44. Following the completion of the sale, the insider now owns 770,496 shares of the company’s stock, valued at $8,174,962.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

NASDAQ TCDA opened at $9.73 on Friday. The company has a debt-to-equity ratio of 584.92, a quick ratio of 4.94 and a current ratio of 4.94. Tricida, Inc. has a fifty-two week low of $3.55 and a fifty-two week high of $12.45. The stock has a market cap of $539.01 million, a PE ratio of -2.83 and a beta of 1.10. The firm’s fifty day moving average price is $9.06 and its two-hundred day moving average price is $8.30.

Tricida (NASDAQ:TCDA – Get Rating) last issued its quarterly earnings data on Tuesday, March 29th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.21). During the same period in the prior year, the company earned ($1.09) EPS. As a group, sell-side analysts predict that Tricida, Inc. will post -2.35 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on TCDA. Needham & Company LLC reiterated a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of Tricida in a research report on Wednesday, March 30th. Zacks Investment Research downgraded shares of Tricida from a “buy” rating to a “hold” rating in a research report on Thursday, January 20th. Finally, The Goldman Sachs Group started coverage on shares of Tricida in a research report on Tuesday, April 12th. They set a “buy” rating and a $25.00 price objective for the company.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Dorsey Wright & Associates purchased a new stake in Tricida in the 1st quarter valued at about $30,000. Sciencast Management LP purchased a new stake in shares of Tricida during the 1st quarter valued at $190,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Tricida by 92.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,270 shares of the company’s stock valued at $27,000 after buying an additional 1,569 shares in the last quarter. Belvedere Trading LLC raised its position in Tricida by 11,449.0% in the 1st quarter. Belvedere Trading LLC now owns 22,867 shares of the company’s stock worth $269,000 after purchasing an additional 22,669 shares during the period. Finally, Norges Bank purchased a new position in Tricida in the 4th quarter worth $437,000. Hedge funds and other institutional investors own 88.47% of the company’s stock.

Tricida Company Profile (Get Rating)

Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.

Featured Articles